MicroParticle Proteomics, LLC (MPP)

MicroParticle Proteomics, LLC (MPP), develops diagnostic tests to identify patients so that treatment or medication can be altered to improve the morbidity and mortality of these high risk patients. MPP's technology is the analysis of disease biomarkers derived from microparticles found in the plasma component of human blood. Microparticles are sub-cellular membranous vesicles that are released byessentially all cell types, especially when cells are under stress. First isolated from plasma through an optimized process, one or more protein biomarkers are selected for the best sensitivity, specificity, positive or negative predictive value as needed and Enzyme-Linked ImmunoSorbent Assay (ELISA) diagnostic tests are developed. MPP's initial focus is on diseases and conditions of the vascular system. Future development will use the patented technology for cancer, autoimmune and neurodegenerative diseases.

Est. 2007